AbCellera Biologics appoints Dr. Sarah Noonberg as CMO to progress AI-based antibody trials and increase clinical development in 2025.

AbCellera Biologics Inc. will be at the critical stage of discovery to clinical implementation in 2025, with several first-in-human trials in progress. The company launched Phase 1 trials in August for two AI-designed antibodies: ABCL635 (first-in-class treatment of menopausal hot flushes) and ABCL575 (moderate-to-severe atopic dermatitis).

In September, AbCellera named Dr. Sarah Noonberg as Chief Medical Officer (CMO) to empower its leadership. The CMO will have a wide range of clinical development knowledge, which is likely to speed up regulatory approvals and lead the company into new areas of therapeutic activities, especially immunological diseases. Another aspect in which the CMO plays a key role is dealing with the increased complexity of the AbCellera pipeline, which now comprises 16 molecules in clinical development as well as 97 partner programs initiated.

Both ABCL575 and ABCL635 exhibit new mechanisms, and ABCL575 is very safe and long-dosing with a very high potency, whereas ABCL635 offers an alternative non-hormonal to fill gaps in menopausal care. Analysts observe that the leadership of the CMO will play a critical role in ensuring that such first-in-human trials are successful.

The company is also driven by its use of AI to find better antibodies, which helps AbCellera speed up development by combining detailed epitope mapping, microfluidics, and improved data analysis. The company will introduce new clinical trials by the end of 2025, increase its integrated manufacturing power, and grow its AI platform, which will enhance the strategic roles of the CMO in the future.